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Abstract
Background: Pasteurella multocida toxin (PMT) is a potent inducer of osteoclast formation. Pigs suffering from an
infection with toxigenic Pasteurella multocida strains develop atrophic rhinitis characterised by a loss of turbinate
bones and conchae. However, on the molecular level the process of bone loss remains largely uncharacterised.
Results: Recently it was found that PMT activates the serine/threonine kinase mammalian target of rapamycin
(mTOR) in fibroblasts. Using RAW264.7 macrophages, we investigated the role of the mTOR complex 1 (mTORC1) in
PMT-mediated osteoclast formation. PMT induces the differentiation of RAW264.7 macrophages into multinucleated,
tartrate resistant acid phosphatase (TRAP) positive osteoclasts that are capable to resorb bone. In the presence of
the mTORC1 inhibitor rapamycin, PMT was significantly less able to induce the formation of TRAP-positive osteoclasts.
Accordingly, the resulting resorption of bone was strongly reduced. A major target of mTOR is the 70 kDa ribosomal
protein S6 kinase 1 (p70 S6K1). Activated p70 S6K1 decreases the expression of programmed cell death protein 4
(PDCD4), a negative transcriptional regulator of osteoclastogenesis, at the protein and gene level. Ultimately this
results in the activation of c-Jun, a component of the activator protein 1 (AP-1) complex, which is a major transcription
factor for the induction of osteoclast-specific genes. We now demonstrate that c-Jun and its downstream
target, the osteoclast-specific bone degrading protease cathepsin K, are upregulated upon PMT treatment in an
mTOR-dependent manner.
Conclusions: Activation of mTOR signalling plays a central role in the formation of osteoclasts through the
bacterial toxin PMT. On the molecular level, PMT-induced activation of mTOR leads to down regulation of
PDCD4, a known repressor of AP-1 complex, culminating in the activation of c-Jun, an essential transcription
factor for triggering osteoclastogenesis.
Background
It is well known that PMT is the causative factor of porcine
atrophic rhinitis. This disease is characterised by increased
osteoclastogenesis and osteoclast activity as well as an in-
hibition of osteoblast function, eventually leading to the
degradation of bone [1]. Despite the economic impact of
this disease due to reduced growth rates of livestock [2],
the molecular mechanisms activated by PMT are just
starting to become unravelled [3]. PMT acts as a deami-
dase for the Gα subunits of heterotrimeric G proteins
[4]. As a consequence, a glutamine residue is changed
into a glutamic acid residue, thereby inhibiting the in-
trinsic GTPase activity of the Gα subunit and rendering
it constitutively active [5]. Recently it has been pub-
lished that PMT activates mTORC1 in fibroblasts [6, 7].
The serine/threonine kinase mTOR is a central signalling
molecule that connects the activity of a cell to environmen-
tal requirements by transducing the extracellular signal into
a change in protein translation. Due to this pivotal role in
cellular maintenance, abnormal mTOR regulation is often
seen in pathologic conditions, including cancer [8]. The
activation of mTORC1 can be inhibited by the anti-fungal
macrolide rapamycin, which originally led to the name
mTOR, for mammalian or mechanistic target of rapamycin.
This kinase belongs to the family of PI3K-related kinases
and its two best-characterised downstream targets are 4E
binding protein-1 (4E-BP1) and p70 S6K1 [9]. The mTOR
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molecule can interact with different complex partners to
create the so-called mTORC1 complex, which is rapamy-
cin sensitive and mTORC2, which is mostly insensitive to
rapamycin, respectively. Interaction partners of mTORC1
are the proteins Raptor, proline-rich Akt substrate
(PRAS40), mammalian lethal with SEC13 protein 8
(mLST8) and DEP domain-containing mTOR-interacting
protein (Deptor), where PRAS40 and Deptor act as nega-
tive regulators for mTOR activity [9]. Phosphorylation of
PRAS40 and Deptor through Akt or mTOR releases them
from the complex and allows signalling [10, 11].
Many clinical data suggest that the inhibition of mTOR
signalling decreases bone erosion in diseases such as
rheumatoid arthritis, multiple myeloma or neurofibroma-
tosis [12, 13]. Investigations of mTOR signal transduction
pathways also suggest that mTOR plays a central role in
osteoclastogenesis, since signalling cascades initiated by
macrophage colony-stimulating factor (MCSF), receptor
activator of nuclear factor kappa-B ligand (RANKL) or
tumour necrosis factor (TNF)-α converge downstream on
mTOR [14]. As PMT is a potent inducer of osteoclast dif-
ferentiation, we investigated the effect of mTOR activation
in a murine macrophage cell line (RAW264.7 cells) that
can be differentiated into osteoclasts [15, 16]. Our studies
reveal a central role for mTOR in PMT-driven osteoclast
formation. In contrast to recent studies where it was
shown that PMT-mediated mTOR activation influences
the proliferation of Swiss3T3 cells through an autocrine
pathway involving the production of connective tissue
growth factor (CTGF) [6], we did not find mTOR to be in-
volved in cellular proliferation of RAW264.7 cells nor in
the production of cytokines. However, PMT-induced for-
mation of functional osteoclasts was reduced in the pres-
ence of the mTORC1 inhibitor rapamycin as shown by
the quantification of TRAP-positive multinucleated cells,
activity of the cysteine protease cathepsin K and the ability
to resorb bone. The mTOR-dependent signalling pathway
involves the activation of the direct mTOR target kinase
p70 S6K1 which ultimately allows the phosphorylation
and subsequent degradation of PDCD4 [17, 18]. Loss of
PDCD4 releases the c-Jun component of the AP-1
transcription factor complex [19]. Through mTORC1-
dependent c-Jun phosphorylation, osteoclastic genes such
as the bone degrading protease cathepsin K are translated.
Results
In order to see whether mTOR activation through PMT
plays a role in immune cells, we stimulated RAW264.7
cells with PMT and checked for mTOR phosphorylation.
Indeed we found that mTOR was activated by treatment
with PMT (Fig. 1a). Interestingly, mTOR phosphoryl-
ation was rapidly induced (1 h) and lasted, due to the
constitutive G protein activation that is a characteristic
feature of PMT signalling [20], for at least 24 h.
Since we observed PMT-induced mTOR phosphoryl-
ation quite early, we verified that the observed mTOR ac-
tivation occurred indeed as a consequence of intracellular
PMT signalling. We therefore investigated the kinetics of
PMT-induced intracellular deamidation of the Gαq sub-
unit by a Gαq antibody, specifically recognising the Q209E
modification that is generated by the targeting and subse-
quent deamidation through PMT [21]. We found that the
uptake of PMT must be much faster than previously sug-
gested as intracellular signalling events can be detected as
early as 15–30 min after stimulation (Fig. 1b).
Phosphorylation of PRAS40 on Thr246 regulates
mTORC1 activity by rendering PRAS40 to prefer bind-
ing to 14-3-3 rather than to mTORC1, for which it is an
inhibitor of kinase activity. When cells were treated with
PMT for 3 h, PRAS40 was robustly phosphorylated on
Thr246. However, PMT-induced phosphorylation of
PRAS40 was unaffected by rapamycin treatment, indi-
cating that PMT-induced PRAS40 phosphorylation is
mTOR independent (Fig. 1c).
Next we investigated the activation of the major
mTOR substrate, the Ser/Thr kinase p70 S6K1 which it-
self is important for the phosphorylation of the riboso-
mal protein S6 involved in mRNA translation. Western
blot analysis for p70 S6K1 phosphorylation on threonine
residue 389, which is critical for activation of its kinase
activity, showed that the protein is highly phosphory-
lated in cells incubated with PMT. As expected, this
phosphorylation was completely abrogated in the pres-
ence of the mTORC1 inhibitor rapamycin (Fig. 1d).
As mTOR has been reported to limit the production of
inflammatory cytokines in immune cells, we checked the
effect of rapamycin on PMT induced cytokines in
RAW264.7 cells using ELISA (Fig. 2 a-d). We determined
the secretion of pro-inflammatory cytokines such as IL-6,
TNF-α or IL12-p40 and the anti-inflammatory cytokine
IL-10, respectively, in response to PMT treatment. As a
positive control for cytokine induction, the toll-like recep-
tor 4 (TLR4) ligand lipopolysaccharide (LPS) was used.
PMT induced the production of IL-6 and TNF-α as re-
ported previously [22, 23], but incubation of the cells with
rapamycin did not alter the effect of PMT on the level of
cytokine induction. IL12-p40 was not induced by PMT
and inhibition of mTOR did not induce IL12-p40 produc-
tion from these cells. Similarly, the anti-inflammatory
cytokine IL-10 was not induced by PMT and rapamycin
treatment did not have any effect on IL-10 production.
These observations suggest that mTOR does not play a
role in the modulation of PMT-mediated cytokine produc-
tion in RAW264.7 macrophages. This is supported by our
previous results that showed that PMT-induced activation
of the NF-κB pathway plays a pivotal role in the induction
of pro-inflammatory cytokines via RhoA/ROCK activation
[24], which is independent of mTOR.
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As RAW264.7 macrophages are capable of differenti-
ating into osteoclasts [15], we investigated the ability of
PMT to trigger osteoclastogenesis in these cells. Figure 3a
shows that PMT-treated cells have a very distinct morph-
ology with a strong activation of cytoskeletal rearrange-
ment, but with no clearly defined actin ring being
detectable. This is presumably caused by the strong activa-
tion of the small GTPase RhoA by PMT [24, 25] which is
known to cause the formation of stress fibres as opposed
to the activation of the related GTPase Rac1 that is
needed for the formation of an actin ring [26]. To verify
that despite the changed morphology these cells are genu-
ine osteoclasts, we performed RT-PCR analysis of typical
osteoclast genes. Figure 3b shows that the genes encoding
for osteoclast associated receptor (OSCAR), nuclear factor
of activated T cells (NFATc1), Cathepsin K, TRAP and the
d2 isoform of vacuolar (H+) ATPase (v-ATPase) Vo do-
main (ATP6v0d2) were upregulated by treatment with
RANKL or PMT, respectively. Although there are differ-
ences in the level of gene induction between the two
Fig. 1 The mTOR pathway is activated in response to PMT. RAW264.7 cells were stimulated with PMT (5 nM) w or w/o rapamycin (10 ng/ml)
for the indicated period of time or were left unstimulated, treated with the solvent control DMSO or rapamycin only. Cells were lysed and the
proteins immunoblotted. (a) mTOR Ser2448 phosphorylation was determined using a specific antibody and β-actin was used as loading
control. (b) To investigate the uptake and intracellular action of PMT, cells were stimulated for the indicated time-points with 5 nM PMT and
lysed. As a control, cells were stimulated with a catalytically inactive mutant of PMT (PMTC1165S). The immunoblot was probed with a specific
antibody detecting the deamidated form of Gαq (Q209E) or total Gαq. (c, d) mTOR-dependent protein phosphorylation from RAW264.7 cells
stimulated with PMT was detected using specific antibodies for PRAS40 (Thr246) or p70 S6K1 (Thr389); ß-actin was used as a loading control.
The results shown are one representative example of three independent experiments
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stimuli, the data suggest that PMT treatment induces dif-
ferentiation towards the osteoclast lineage. To investigate
this in more detail, we stimulated RAW264.7 cells with
PMT or soluble RANKL and incubated the cells for 3 days
to allow for cell differentiation. PMT-treated cells were also
grown in the presence of rapamycin, to check for mTOR-
mediated effects. Osteoclast differentiation was then evalu-
ated by microscopy checking for the expression of the
osteoclast specific phosphatase TRAP and the presence of
multiple nuclei (≥3). Figure 3c shows that PMT treatment
induced osteoclast differentiation in a concentration-
dependent manner. Inhibition of mTORC1 signalling in
PMT-treated cells by rapamycin reduced the osteoclast for-
mation significantly, even at the highest concentration of
PMT. We therefore conclude that a crucial function of
PMT-mediated mTOR activation in macrophages is to
support osteoclast differentiation.
To elucidate the signalling pathways of mTOR in PMT-
treated macrophages, we had a look at the major activa-
tion pathway for mTOR, which is the activation of the PI3
kinase/Akt pathway. In contrast to other PMT-induced
signalling pathways, Akt is activated through the Gβγ
subunit that is released from the activated G protein, but
not through the deamidated Gα subunit itself [27].
Figure 4a shows that PMT induces the activation of Akt
by phosphorylation on residue Thr308 in RAW264.7 cells
and that this activation is sustained till overnight exposure
to PMT. Interestingly, we observed that PMT-induced
Akt activation lies upstream of the mTOR complex at
early time-points (3 h, 6 h) since treatment with rapamy-
cin did not abrogate Akt phosphorylation. However, after
prolonged rapamycin treatment (o.n. stimulation) the
phosphorylation of Akt decreases (Fig. 4a). This suggests a
potential involvement of mTORC2, which has Akt as a
downstream target, and is known to get rapamycin-
sensitive after prolonged rapamycin treatment [28].
The heterodimeric transcription factor AP-1 is composed
of subunits from the c-Jun and c-Fos families and plays a
central role for the induction of osteoclastic genes in co-
operation with NFATc1. The activity of AP-1 can be sup-
pressed by PDCD4, which in turn is negatively regulated by
activation of the mTOR substrate p70 S6K1 [17, 29].
Decreased PDCD4 levels allow the activation of AP-1,
through release of c-Jun molecules from their repressor
Fig. 2 PMT stimulated release of TNF-α or IL-6 is independent of the mTOR pathway. RAW264.7 cells were stimulated with PMT (5 nM)
w or w/o pre-incubation with rapamycin (10 ng/ml) for 1 h. As control, cells were untreated, treated with the solvent control DMSO, with
rapamycin or LPS (100 ng/ml) as positive control. After 24 h, supernatants were removed and subjected to ELISA for the measurement of
(a) IL-6-, (b) TNF-α-, (c) IL12p40- or (d) IL-10 release. Shown are the results of three independent experiments (mean ± SD; n = 3)
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PDCD4. This subsequently leads to c-Jun phosphorylation
and activation by JNK [19] which ultimately results in the
release of the suppression of osteoclastic genes. Untreated
RAW264.7 cells show a robust expression of PDCD4 that
can be further enhanced by treatment with rapamycin
(Fig. 4b). On the other hand, stimulation of the cells with
PMT for 3 to 6 h strongly decreased the levels of the
negative regulator PDCD4 and prolonged treatment with
PMT (o.n) resulted in the complete loss of PDCD4 expres-
sion. Apart from the regulation of PDCD4 protein levels
by mTOR, Pdcd4 transcription can also be negatively
affected by this kinase [30, 31]. When we performed
RT-PCR analysis of Pdcd4 expression, we found that
PMT treatment leads to a significant reduction in gene
Fig. 3 Osteoclast differentiation of RAW264.7 cells with PMT requires mTOR activation and shows a distinct morphology. (a) RAW264.7 cells were
stimulated with PMT (5 nM) or RANKL (50 ng/ml) as a positive control for osteoclast differentiation. After 4 days of stimulation, cells were labelled
in an enzymatic reaction for the activity of the enzyme TRAP (ELF97) in green. Nuclei were stained with DAPI (blue) and the cytoskeleton with
TRITC-Phalloidin (red). Pictures were taken by confocal laser scanning microscopy and representative pictures are shown (number of independent
experiments n≥3). (b) RAW264.7 cells were seeded in 6-well plates, stimulated with 5 nM PMT or 50 ng/ml RANKL for 24 h-48 h before
preparation of cDNAs. Quantitative RT-PCR was performed and the graphs display the relative expression for Oscar, Nfatc1, Ctsk (cathepsin K),
Acp5 (TRAP) and ATP6v0d2 normalized to S29 expression. The indicated standard deviation was obtained from four experiments (mean ± SD;
n = 4 and n = 3 for Nfatc1). Statistical analysis was performed using an unpaired Student’s t-test comparing gene expression to the
untreated sample (*: p ≤ 0.05; **: p ≤ 0.005; ***:p ≤ 0.0005). (c) The numbers of conventionally TRAP-stained cells were quantified after
3 days of stimulation with the indicated concentrations of PMT or 50 ng/ml RANKL in the presence or absence of rapamycin (10 ng/
ml). The graph displays the number of TRAP-positive, multinucleated (≥3) cells. The indicated standard deviation was calculated from
three independent experiments (mean ± SD; n = 3). Statistical analysis was performed using an unpaired Student’s t-test (***: p ≤ 0.0005)
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expression that can be reversed by rapamycin treatment
(Fig. 4c). Treatment with RANKL also reduced Pdcd4
expression, however, theses changes were statistically not
significant. Next, we investigated the effect of Pdcd4
expression on the activation of downstream genes. Cathep-
sin K was described to be an AP-1-dependent gene in
RAW264.7 cells [32]. Since Ctsk was strongly induced
after treatment with PMT (Fig. 3b), we used this gene as
Fig. 4 PMT activates targets known to be important for osteoclast differentiation. RAW264.7 cells were left untreated or stimulated with PMT (5
nM) w or w/o rapamycin (10 ng/ml). After incubation for the indicated period of times, cells were examined for Akt (Thr308) phosphorylation or
the total amount of Akt (a) and PDCD4 (b). Shown are representative data from three independent experiments. (c) Pdcd4 expression (mean ± SD; n= 2)
was determined by RT-PCR in the presence or absence of rapamycin (10 ng/ml) using cells treated with 5 nM PMT or 50 ng/ml RANKL for 6 h (n = 2).
(d) PDCD4 siRNA transfection was performed according to the manufacturer’s protocol. RT-PCR of Pdcd4 expression was determined after
36 h and was normalized to S29 expression (n = 3). Statistical analysis was performed using a paired Student’s t-test (*: p≤ 0.05). (e) 24 h after siRNA
transfection, cells were stimulated for 12 h with PMT (5 nM) in the presence or absence of 10 ng/ml rapamycin. The expression of Ctsk was monitored
by RT-PCR (mean ± SD; n= 2). Analysis for (d) and (e) was performed using the same samples of cDNA (*: p≤ 0.05). (f ) Phosphorylation of c-Jun (Ser63)
and nuclear localisation of c-Jun (g) was detected by western blot analysis. Shown are representative data from three independent experiments
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a read-out in Pdcd4 knock-down experiments. RT-PCR
analysis confirmed a siRNA-mediated reduction by app.
50% of Pdcd4 expression compared to untreated cells
or control siRNA-treated cells (Fig. 4d). This was cor-
roborated by western blot analysis (Additional file 1:
Figure S1). The downregulation of Pdcd4 in the absence
of a signal triggering AP-1 activation does not induce
the transcription of downstream genes, however, PMT
treatment induced the expression of Ctsk in all condi-
tions. This effect was rapamycin-sensitive only in the
sets of control cells, whereas the Pdcd4 knock-down
rendered the Ctsk expression independent of mTOR
(Fig. 4e).
When we investigated c-Jun activation (Fig. 4f ), we
found that PMT stimulation rapidly induced c-Jun phos-
phorylation (3 h). However, in contrast to p70s6K activa-
tion, only the prolonged stimulation with PMT (o.n.)
was mTOR-dependent, while c-Jun activation observed
at earlier time-points occurred independently of mTOR.
As expected, PMT treatment also led to the rapid accu-
mulation of c-Jun molecules in the nucleus (Fig. 4g).
Again, the translocation of c-Jun to the nucleus was only
affected after prolonged treatment with rapamycin.
To investigate the effects of rapamaycin on the func-
tional activity of osteoclasts, we also determined the activ-
ity of cellular cathepsin K protein using a reporter assay
that releases a fluorescent dye from a sample probe when
cleaved by active cathepsin K (Fig. 5a). Cathepsin K was
highly induced at PMTconcentrations ranging from 0.5 to
5 nM PMT. However, concentrations as low as 0.05 nM
were enough to allow detectable production of cathepsin
K (Fig. 5a). As our findings indicate that the activation of
AP-1 occurs mTORC1 dependently, we hypothesized that
treatment with rapamycin would inhibit cathepsin K activ-
ity. Indeed, we found cathepsin K activity to be completely
abrogated in the presence of rapamycin (Fig. 5b).
Next we tested the degradation of bone matrix using a
fluorescent bone resorption assay, where the release of a
fluorescent dye into the cell culture supernatant is used
to quantify the resorptive activity of osteoclasts on fluor-
esceinated calcium phosphate plates (Fig. 5c). Here, we
observed a decrease in PMT-mediated bone-resorption
in the presence of rapamycin due to a decrease in func-
tional osteoclasts (Fig. 3c). Bone resorption could also be
detected using bovine bone slices and subsequent tolui-
dine staining. We observed that the bone resorption by
PMT-induced osteoclasts was comparable to RANKL-
differentiated osteoclasts (Fig. 5d). When osteoclasts were
cultivated on bone slices in the presence or absence of
rapamycin, a significant reduction of the resorbed pit area
was observed in the presence of rapamycin (Fig. 5e). To
make sure that the reduced activity of rapamycin-treated
osteoclasts is not due to an increase in the number of
apoptotic cells, we performed a caspase3/7-Glo assay. The
data prove that rapamycin treatment does not lead to an
increase in apoptosis (Fig. 5f).
Discussion
PMT-expressing toxigenic bacterial strains are known to
cause bone degradation in pigs. However, it is currently
unclear how PMT drives this process and how the bac-
teria might benefit from the increased osteoclast differ-
entiation. As it was recently shown that PMT is able to
activate mTORC1 in a fibroblast cell line [6, 7], we in-
vestigated if mTOR activation is important for the differ-
entiation of macrophages into osteoclasts. We found
that stimulation with PMT results in osteoclast differenti-
ation in an mTOR-dependent manner in RAW264.7 mac-
rophages. This supports clinical data using the mTOR
inhibitor rapamycin as well as data investigating mTOR
related signalling pathways after cytokine-mediated osteo-
clast differentiation that suggest that mTOR is an import-
ant factor in bone degradation.
In immune cells activation of the mTOR pathway was
described to be part of the response to stimulation by con-
served microbial patterns which shifts the cytokine bal-
ance towards a diminished release of certain pro-
inflammatory cytokines such as IL-6, TNF-α and IL12-p40
and the increased secretion of the anti-inflammatory cyto-
kine IL-10 [33–35]. Analysis whether similar effects on
cytokine secretion play a role in PMT-induced activation
of the mTOR pathway revealed that the PMT-induced se-
cretion of IL-6 and TNF-α occurs independently of the
mTOR pathway (Fig. 2). The pro-inflammatory cytokines
IL-6 and TNF-α are known to have a synergistic effect on
the activation of the transcription factor AP-1, which was
shown to be crucial for osteoclast differentiation [36]. In
addition, TNF-α and IL-6 are potent activators of mTOR
[14]. It is therefore likely that the observed osteoclast dif-
ferentiation is a mixture of direct, PMT-mediated signal-
ling events that are related to G protein activation and
signal transduction pathways related to the PMT-induced
secretion of osteoclastogenic cytokines. Further work will
be necessary to delineate the influence of cytokines on
PMT-induced osteoclast formation in detail.
We propose the mTOR-dependent removal of the re-
pressor PDCD4 as a central switch to allow osteoclast dif-
ferentiation by turning on the transcription of osteoclast
specific genes through AP-1. PDCD4 activity can be con-
trolled by regulating its stability. Cellular degradation of
PDCD4 was shown to be induced by phosphorylation in
mTOR-related signalling pathways through p70 S6K1 or
Akt, respectively. This phosphorylation enhances binding
of the E3-ubiquitin ligase ß-TrCP1 and accelerates the
proteasomal degradation of PDCD4 [17, 18]. Here we
show that PDCD4 is downregulated after PMT stimula-
tion and that this is indeed dependent on mTOR activa-
tion, since treatment of the cells with rapamycin stabilized
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Fig. 5 PMT-stimulated mTOR activation is required for the full functional activity of the osteoclasts. (a) Lysates of cells stimulated for 4 days with
PMT concentrations ranging from 10 pM to 5 nM were analyzed for activity of cathepsin K (cleavage of its specific substrate) by fluorescence
detection. (b) RAW264.7 cells stimulated with PMT (5 nM) w or w/o rapamycin (10 ng/ml) were analyzed for cathepsin K activity by fluorescence
detection. As controls, cells were treated with rapamycin, the solvent control DMSO or were left untreated. (c) Cells were plated and stimulated
on fluoresceinated calcium phosphate plates for 6 days to allow osteoclast differentiation. A fluorescent dye released into the supernatant
dependent on the degree of bone resorption was measured with a fluorometer. (d ) Osteoclasts were differentiated with RANKL and PMT,
respectively, on bone slices and the pit area of resorbed bone was determined. (e) Bone resorption induced by RANKL, PMT or PMT in the
presence of rapamycin was quantified by determining the pit area. (f) Cellular apoptosis was determined by performing a caspase-Glo 3/7
Assay. Cells were incubated for 48 h with PMT (5 nM), the solvent control DMSO, rapamycin (10 ng/ml) or left untreated. As a positive
control for apoptosis, cells were incubated with 1 μM doxorubicin for 6 h. Cells were lysed and the luminescence signal was recorded. The
indicated standard deviations of all figures were calculated from three independent experiments (mean ± SD; n = 3). Statistical analysis for
all graphs was performed by unpaired Student’s t-test (*: p ≤ 0.05, **: p ≤0.005, ***: p ≤ 0.0005****: p ≤ 0.0001)
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PDCD4 expression. It is possible that this process is add-
itionally sustained by the secretion of the PMT-induced
pro-inflammatory cytokines IL-6 and TNF-α, as it was
found that inflammatory conditions can support proteaso-
mal degradation of PDCD4 in macrophages [18].
Besides the regulation of PDCD4 protein levels by
degradation, its expression is also controlled by protein
biosynthesis. The oncomir miR-21 [37] has been de-
scribed to be involved in this process by inhibiting
translation of Pdcd4 mRNA [38]. Furthermore, miR-21
is well known to be important for RANKL-driven oste-
oclastogenesis by downregulation of PDCD4 resulting
in AP-1 transactivation and the transcription of osteo-
clast genes [39]. When we analysed miR-21 expression
(Additional file 2: Figure S2A) we detected a strong up-
regulation of this miRNA after PMT treatment. How-
ever, miR-21 was not rapamycin-dependent.
We therefore propose that PMT-induced miR-21 up-
regulation is mediated by an alternative pathway of
miR-21 induction [40–43] that involves the signal
transducer and activator of transcription (STAT)-3, a
well-known downstream target of PMT signalling [44]
(Additional file 2: Figure S2B). Similar to miR-21
expression, PMT-mediated STAT-3 activation was also
rapamycin-independent.
Consequently, transfection of a miR-21 antagomir did
not enhance PDCD4 levels after PMT stimulation. This
corroborates our data that PDCD4 is regulated via mTOR
activation but not via miR-21 (Additional file 2: Figure
S2C,D). Data by Sugatani et al. point towards a pivotal
role of miR-21 in osteoclastogenesis [39]. Considering that
the knock-out of Pdcd4 does not lead to a osteopenic
phenotype in the mouse, miR-21 target genes other than
Pdcd4 play an important role in osteoclastogenesis and
are likely targeted by PMT.
Since PDCD4 was described to be central in the
transactivation of the AP-1 component c-Jun [19], we
investigated whether c-Jun is phosphorylated at its
transactivation site Ser63 upon treatment of the cells
with PMT (Fig. 4f ). We found phosphorylation of Ser
63 already at early time-points (3 h) through a mechan-
ism that appears to be independent of mTORC1. At
later time points (24 h) the phosphorylation of c-Jun
was dependent on mTORC1. The mTOR-independent,
early p-c-Jun molecules (Ser63) might for example be
forming heterodimers with other transcriptions factors
such as proteins of the ATF, c/EBP, Maf or NF-E2 family
driving the transcription of genes not primarily involved
in osteoclastogenesis but other cellular process [45]. It also
appears plausible that PMT triggers dynamic exchanges of
repressive and activating chromatin modifiers (e.g. histone
acetyltransferases and deacetylases) associated with AP-1,
as these enzymes were shown to control AP-1 dependent
gene expression events. Both possibilities require further
investigation. At later time points (o.n.), c-Jun is phos-
phorylated via an mTOR-dependent mechanism and the
dimers formed are probably preferentially c-Jun/c-Fos di-
mers, since these were described before to be crucial for
osteoclastogenesis [46, 47].
Conclusions
In summary, we show that PMT-induced osteoclast dif-
ferentiation requires mTORC1 activity, which eventually
allows the expression of osteoclast specific genes such as
cathepsin K via a pathway involving the downregulation
of the transcriptional repressor PDCD4. PDCD4 degrad-
ation allows JNK to phosphorylate the c-Jun component
of the AP-1 complex and transcriptional activation of
genes such as cathepsin K. Our data indicate that signal-
ling events related to PMT-induced G protein activation
as well as cytokine-induced signals play a role for the ac-
tivation of mTOR and its role in osteoclast formation.
Methods
Reagents
Recombinant PMT and the catalytically inactive mutant
PMTC1165S were kindly provided by Dr. Joachim Orth
and Prof. Klaus Aktories (Freiburg). Purification of PMT
and control of endotoxin contaminations are described
elsewhere [24].
Cell culture
RAW264.7 cells (murine monocytic cell line; ATCC)
were cultured in DMEM, supplemented with 10 % heat-
inactivated foetal calf serum (Bio West) and 100 U/ml
penicillin and 10 μg/ml streptomycin (PAA). The cells
were cultivated in cell culture flasks (75 cm2; Sarstedt) at
humidified atmosphere (95 %), 5 % CO2 and 37 °C
temperature. The cells were split every 2–3 days in a
ratio of 1:30.
Stimulation
Cells were stimulated with 0.01-5 nM PMT or 50 ng/ml
rec. mouse RANKL (R&D Systems).
Antibodies and inhibitors
Antibodies against p-mTOR (Ser2448), p-p70 S6K1
(Thr389), p-PRAS40 (Thr246), PDCD4, c-Jun, p-c-Jun
(Ser63), p-STAT-3 (Tyr705), STAT-3, histonH3, ß-
actin were purchased from Cell Signaling Technology.
An antibody that recognizes the Q209E modification
of Gαq was a gift of Prof. S. Kamitami (Osaka, Japan).
Secondary HRP-linked antibodies were obtained from
Cell Signaling Technology (anti-rabbit-IgG) or abcam
(anti-rat-IgG). The mTOR Inhibitor I (rapamycin) was
purchased from Calbiochem and used at 10 ng/ml.
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Quantitative real-time PCR
7.5 × 105 RAW264.7 cells were seeded per well in 6-
well plates and then stimulated as indicated. RNA was
extracted using High- Pure RNA isolation kit (Roche),
according to the manufactures’ protocol. cDNA was pre-
pared by using Revert Aid First strand cDNA synthesis
kit (Thermo Scientific). Quantitative RT-PCR was per-
formed using SYBR Green Rox mix (Thermo Scientific)
with the primers listed in Table 1. The RT-PCR was run
at the 7900 HT Fast Real-Time PCR System (AB Applied
Biosystems). An initial denaturation step of 10 min at
95 °C was common for all genes, but the following cycle
for annealing and amplification was different. For Acp5,
Nfatc1and Pdcd4 (40 cycles at 95 °C for 15 s and at 58 °C
for 1 min); Ctsk, ATP6v0d2 and Oscar (40 cycles at 95 °C
for 15 s, 60 °C for 30 s and 72 °C for 30 s). As
normalization control S29 was used. Relative expression
(rE) was calculated as rE = 1/(2ΔCt). Primers can be found
in Table 1.
ELISA
The production of IL-6, TNF-α, IL-12(p40) and IL-10
was measured by commercial assays: mouse IL-6 ELISA
MAX™ Standard Set (BioLegend), mouse TNF-α ELISA
MAX™ (BioLegend) Standard Set, the BD OptEIA™
Mouse IL-12(p40) ELISA Set (BD Biosciences) or BD
OptEIA™ Mouse IL-10 ELISA Set (BD Biosciences). The
ELISA assays were conducted according to the protocols
of the distributing companies. The TecanGENios Pro
plate reader was used to measure the detectable signal.
The results were analyzed with the Magellan5 software.
Western blot analysis
1 x 106 cells were stimulated in 2 ml of medium in a 6-
well-format as indicated with or without the inhibitor rapa-
mycin (pre-incubated for 1 h before PMT-stimulation) or
solvent control DMSO. Untreated control cells were har-
vested at the time-point corresponding to the longest time
of stimulated cells in this experiment. For the lysis, cells
were washed with ice-cold PBS in the well before the cells
were scraped of in ice-cold PBS. Cell pellets were resus-
pended in 100 μl of 1xNP40 buffer (1 % NP-40, 150 mM
NaCl, 20 mM Tris (pH 7,4), 10 mM NaF, 1 mM EDTA,
1 mM MgCl2, 1 mM Na3VO4, 10 % glycerin) freshly sup-
plemented with a Phosphatase- and Protease-Inhibitor
Cocktail (Roche). Cells were lysed for 40 min at 4 °C and
centrifuged to remove cell debris. Lysates were boiled
(95 °C; 3 min) in sample loading buffer (50 mM Tris; 2 %
SDS, 10 % Glycerol, 100 mM ß-mercaptoethanol) and
separated by SDS-PAGE (4-20 % gradient polyacrylamid
gel, Anamed). Proteins were transferred to nitrocellulose
membrane via semi-dry western blot, blocked in TBST
(5 % BSA) for 1 h at RT before the membranes were incu-
bated with the primary antibody, diluted as suggested by
Cell Signaling Technology overnight (o.n.) at 4 °C. After
1 h incubation with the secondary antibody (HRP-coupled)
(anti-rabbit 1:1000, anti-rat 1:10,000), proteins were de-
tected by enhanced chemiluminescence.
For the detection of p-mTOR (Ser2448), proteins were
transferred via a wet-western-blot technique. Lysates were
loaded on 7 % SDS-Tris gels and run at 130 V. Proteins
were blotted onto a PVDF-Membrane (Roth) at 150 mA
for 150 min. Membranes were briefly washed in PBST and
then blocked for 1 h in PBST with 5 % milk. Membranes
were incubated o.n. in the primary antibody in PBST.
Then they were washed three times and then incubated
for 1 h with the secondary antibody (Pierce). After wash-
ing three times in PBST, membranes were incubated with
ECL detection solution (Millipore) and developed.
Confocal microscopy
RAW264.7 cells were plated on Poly-D-Lysin-coated
coverslips (Sigma Aldrich) in 24-well plates at a density of
1 x 105 cells per well in 1 ml of medium. Cells were pre-
incubated with rapamycin or corresponding solvent con-
trol DMSO for 1 h before cells were stimulated with PMT
or RANKL or left untreated. After 4 days of differenti-
ation, cells with enzymatic activity for the enzyme TRAP
were fluorescence-marked using the ELF 97 phosphatase
substrate (Molecular Probes) in an enzyme-labelled fluor-
escence assay as described by Filgueira et al. [48]. Further-
more the actin filament of the cell was labelled with
TRITC-conjugated Phalloidin (Sigma Aldrich) and the
nuclei with DAPI (life technology) to distinguish TRAP-
Table 1 Primers used for RT-PCR
Gene Forward Reverse
Acp5 5´-TTC CAG GAG ACC TTT GAG GA-3´ 5´-TTC CAG GAG ACC TTT GAG GA-3´
Oscar 5´-AGG GAA ACC TCA TCC GTT TG-3´ 5´-GAG CCG GAA ATA AGG CAC AG-3´
Ctsk 5´-AGG GAA GCA AGC ACT GGA TA −3´ 5´-GCT GGC TGG AAT CAC ATC TT-3´
Atp6v0d2 5´-TCA GAT CTC TTC AAG GCT GTG CTG-3´ 5´-GTG CCA AAT GAG TTC AGA GTG ATG-3´
Nfatc1 5´-GGG TCA GTG TGA CCG AGG AT-3´ 5´-GGA AGT CAG AAG TGG GTG GA-3´
S29 5´-AGC CGA CTC GTT CCT TTC TC-3´ 5´-CGT ATT TGC GGA TCA GAC C-3´
Pdcd4 5´-CAC TCA TAC TCT GTT CTT −3´ 5´-`TCC ATC TCC TTC ACT TAC −3´
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positive and multinucleated osteoclasts from undifferenti-
ated RAW264.7 cells. Cells were fixed with 3.7 % parafor-
maldehyde for 15 min, washed with PBS and permeabilised
with 0.2 % TritonX100 for 20 min, washed three times with
PBS and incubated with 1 ng/μl TRITC-Phalloidin (PBS;
1 % BSA) for 30 min. Cells were washed three times with
PBS and incubated in 50 μl ELF97 phosphatase substrate
solution containing tartrate for 13 min, RT. The enzymatic
reaction with TRAP was stopped by placing the coverslips
for 3 × 4 min on 50 μl stopping solution (Levamisole). After
further 3× washing (PBS), cells were incubated with 300
nM DAPI in PBS for 10 min. Cells were washed 3× in PBS,
1x in H2Odd before they were mounted.
To visualize the cells, a confocal laser scanning micro-
scope (Leica) was used with a 1.4 NA 63× immersion oil
objective. DAPI and ELF97 were excited with UV-light
(405 nm) while TRITC was excited with visible light
(561 nm). Pictures were taken at 400 Hz with 4× line
and frame average.
Cathepsin K activity assay
RAW264.7 cells were seeded at 1 × 105 cells per well in
a 6-well plate. Cells were pre-treated with rapamycin or
DMSO for 1 h before cells were stimulated with PMT or
left untreated. After 4 days of differentiation, a cathepsin
K Activity Assay was performed (Abcam). Cells were
lysed in 50 μl of cathepsin K cell lysis buffer and incu-
bated on ice for 10 min. Cell debris were centrifuged at
15,000 rpm for 5 min and the supernatants were re-
moved. The amount of protein in the lysates was deter-
mined with a BCA Assay (Pierce) and the amount of
protein for each assay was adjusted to 10 μg of protein
in 50 μl of lysis buffer per well of a 96-well plate. 50 μl
of cathepsin K reaction buffer was added to each well.
The Ac-LR-AFC substrate was added to a final concen-
tration of 200 μM and the plate was incubated for 1 h at
37 °C. Fluorescence was measured with a microplate-
reader (FLUOstar OPTIMA; BMG LABTECH) with an
excitation of 355 nm and an emission of 520 nm.
Small interfering RNA (siRNA) transfection
PDCD4 and control small interfering RNA (siRNA), trans-
fection medium and transfection reagent were procured
from Santa Cruz Biotechnology. siRNA transfection was
carried out according to the manufacturer’s protocol.
Briefly, 2 × 105 RAW264.7 cells were plated per well in a
6-well plate 24 h prior to transfection. siRNA duplex (60
pmol) was mixed with transfection reagent in transfection
medium and added to cells . After 6 h, 1 ml of medium
(RPMI 1640 plus 20 % FCS) was added per well; 12 h later,
this medium was replaced with standard culture medium
(RPMI 1640 plus 10 % FCS). After 24 h, cells were stimu-
lated with PMT or PMT+ rapamycin or rapamycin alone
for 12 h for qRT-PCR analysis.
Caspase-Glo 3/7 assay
4 × 103 cells were plated per well in a 96-well plate (clear
bottom) and were cultivated in FCS-reduced medium
(2.5 % heat-inactivated foetal calf serum) and stimulated
with PMT and rapamycin or solvent control DMSO for
48 h (triplicates). Apoptosis was measured using the
caspase-Glo® 3/7 Assay (Promega). As positive control,
1 μM doxorubicin (Sigma) was incubated for 6 h before
the measurement was performed as described in the
manual of the assay provider.
Fluorescent bone resorption assay
1 × 104 RAW264.7 cells were seeded per well in phenol
red free DMEM containing 10 % FBS using a 48-well
fluoresceinated calcium phosphate coated plate (Cosmo
Bio Co., LTD) as described by manufacturer’s protocol.
For differentiation, cells were treated with 5 nM PMT
for 6 days, with a change of the medium on every third
day. Bone resorption activity was evaluated by measuring
the fluorescence intensity at an excitation wavelength of
485 nm and emission wavelength of 590 nm of the con-
ditioned medium as recommended by manufacturer’s
protocol using FLUOStar Optima (BMG Labtech).
Determination of bone resorption pit area
5 × 104 RAW264.7 cells were plated in 1 ml of complete
medium in 24-well plates. Cells were either untreated or
treated with PMT, rapamycin or in combination of PMT
and rapamycin for 3 days. Cells were then transferred to
96 well plate containing bovine cortical bone slices (Bone-
slices.com) and were treated as mentioned before for
7 days, with a change of the medium on every third day.
For measurement of resorbed area, the bovine cortical
bone slices were washed with PBS, incubated in 5 % so-
dium hypochlorite for 1 h, washed twice with water, and
stained with 0.1 % toluidine blue. The pits developed a
blue to purple colour. The resorbed area was calculated
from micro images with Adobe® Photoshop® CS5.
TRAP staining
5 × 104 RAW264.7 cells were plated in 1 ml of complete
medium in 24-well plates. Cells were treated either with
RANKL (50 ng/ml) or various concentration of PMT for
3 days. Cells were then fixed and stained using Acid
Phosphatase, Leukocyte (TRAP) Kit (Sigma, St Louis,
MO, USA). TRAP positive cells with three or more
nuclei were scored as osteoclasts.
Statistical analysis
Data are presented as mean ± SD. Statistical analysis was
performed using an unpaired or paired, two-tailed Stu-
dent’s t-test as stated in the corresponding figure legends
(*p ≤ 0.05, **p ≤ 0.005,***p ≤ 0.0005) using the Prism 6.0
software (La Jolla, CA,USA).
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Additional files
Additional file 1: Figure S1. SiRNA-mediated knock-down of PDCD4.
PDCD4 siRNA transfection was performed according to the manufacturer’s
protocol. Transfected cells were lysed 48 h after transfection and β-actin
was used as a loading control (n = 2). (JPEG 244 kb)
Additional file 2: Figure S2. (a) PMT-mediated miR-21 activation is
mTOR-independent. MiR-21 expression of PMT-stimulated cells was
determined by RT-PCR and the effects of mTOR pathway inhibition by
rapamycin (10 ng/ml) were addressed (normalisation to RnU6b). The
indicated standard deviation was calculated from three independent
experiments (mean ± SD; n = 3). Statistical analysis was performed using
an unpaired Student’s t-test (***p ≤ 0.005). (b) p-STAT-3 (Tyr705) and
STAT-3 was detected by immunoblotting as described above. (c) Uptake of
the fluorescent 5’6-FAM antagomiR 21 was detected 24 h after transfection by
fluorescent microscopy. As controls, untransfected cells and cells transfected
with non = fluorescent control antogomiR were used (n= 3). (d) PDCD4
expression was monitored by western blotting in cells 48 h after transfection
with a antagomiR 21 or control antagomiR in the presence or absence of a
PMT stimulus (12 h at 5 nM). (JPEG 798 kb)
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